• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项使用5-氨基酮戊酸和蓝光进行光动力疗法治疗上肢光化性角化病的随机、双盲、双侧个体内、载体对照试验。

A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities.

作者信息

Taub Amy Forman, Garretson Cara Beth

机构信息

Advanced Dermatology, Lincolnshire, IL 60069, USA.

出版信息

J Drugs Dermatol. 2011 Sep;10(9):1049-56.

PMID:22052276
Abstract

BACKGROUND/OBJECTIVE: Actinic keratoses (AKs) on the upper extremities are difficult to treat. This study compares the efficacy and tolerability of photodynamic therapy (PDT) using 20% 5-aminolevulinic acid solution (ALA) and blue light versus ALA vehicle and blue light for the treatment of AKs of the dorsal hand and forearm.

METHODS

Subjects were treated twice at an eight-week interval by ALA with blue light on one hand and forearm and with ALA vehicle and blue light on the contralateral hand and forearm. ALA incubation time was two hours under occlusion. Efficacy and tolerability were compared.

RESULTS

The mean lesion count reductions (58.4 ± 22.2% and 24.8 ± s20.6% four weeks after the second treatment for the ALA and vehicle-treated sides, respectively) differed significantly (P=0.0004). Eleven of 15 subjects (73%) in the ALA-treated side achieved at least 50 percent reduction in lesion count compared to only two subjects (13%) in the vehicle-treated side four weeks after the second treatment. The difference was significant (P=0.0143). Photodamage grade reduction was also significant (P=0.0309) after the second treatment. Subject satisfaction was moderate to very satisfied (86.7%) on the ALA-treated side. Transient adverse events were significantly greater on the ALA-treated side for erythema (P=0.0011), edema (P=0.0199) and stinging and burning (P=0.0016) 48 hours after the first treatment.

CONCLUSIONS

Two sessions of PDT using ALA with blue light is a moderately effective, well-tolerated treatment of actinic keratoses of the dorsal hand and forearm.

摘要

背景/目的:上肢的光化性角化病(AKs)难以治疗。本研究比较了使用20% 5-氨基酮戊酸溶液(ALA)和蓝光的光动力疗法(PDT)与ALA赋形剂和蓝光治疗手背和前臂AKs的疗效和耐受性。

方法

受试者双手和双侧前臂分别接受治疗,一侧手背和前臂用ALA加蓝光治疗,另一侧用ALA赋形剂加蓝光治疗,间隔8周治疗两次。ALA封闭孵育时间为两小时。比较疗效和耐受性。

结果

第二次治疗后四周,ALA治疗侧和赋形剂治疗侧的平均皮损计数减少率分别为(58.4±22.2%和24.8±20.6%),差异有统计学意义(P=0.0004)。第二次治疗后四周,ALA治疗侧15名受试者中有11名(73%)皮损计数至少减少50%,而赋形剂治疗侧只有2名受试者(13%)达到这一效果。差异有统计学意义(P=0.0143)。第二次治疗后光损伤分级降低也有统计学意义(P=0.0309)。ALA治疗侧受试者满意度为中度至非常满意(86.7%)。第一次治疗后48小时,ALA治疗侧的红斑(P=0.0011)、水肿(P=0.0199)以及刺痛和灼痛(P=0.0016)等短暂不良事件明显更多。

结论

使用ALA和蓝光进行两次光动力疗法是治疗手背和前臂光化性角化病的一种疗效中等、耐受性良好的治疗方法。

相似文献

1
A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities.一项使用5-氨基酮戊酸和蓝光进行光动力疗法治疗上肢光化性角化病的随机、双盲、双侧个体内、载体对照试验。
J Drugs Dermatol. 2011 Sep;10(9):1049-56.
2
A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period.一项多中心、随机、赋形剂对照的2期研究,评估20%盐酸氨基酮戊酸局部溶液蓝光光动力疗法治疗上肢光化性角化病:药物孵育期封包的效果
J Drugs Dermatol. 2012 Dec;11(12):1483-9.
3
Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm.维甲酸预处理对光动力疗法治疗手部和前臂光化性角化病患者疗效的影响。
J Drugs Dermatol. 2011 Oct;10(10):1124-32.
4
Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials.外用氨基酮戊酸溶液联合可见蓝光光动力疗法治疗面部和头皮多发性光化性角化病:研究者设盲的3期多中心试验。
Arch Dermatol. 2004 Jan;140(1):41-6. doi: 10.1001/archderm.140.1.41.
5
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies.新型自粘式5-氨基乙酰丙酸贴片光动力疗法的优化:两项随机对照III期研究结果
Br J Dermatol. 2009 May;160(5):1066-74. doi: 10.1111/j.1365-2133.2009.09040.x. Epub 2009 Feb 16.
6
Severe cutaneous reaction to photodynamic therapy with blue light.蓝光光动力疗法引起的严重皮肤反应。
J Drugs Dermatol. 2011 Sep;10(9):1057-8.
7
Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A One-Year Follow-up Study.温度调制光动力疗法治疗四肢光化性角化病:一项为期一年的随访研究
Dermatol Surg. 2015 Nov;41(11):1290-5. doi: 10.1097/DSS.0000000000000512.
8
Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.用氨基酮戊酸光动力疗法(ALA-PDT)或0.015%鬼臼毒素凝胶治疗面部光化性角化病,以及是否在ALA-PDT治疗之前进行治疗。
J Drugs Dermatol. 2014 Nov;13(11):1353-6.
9
Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.上肢光化性角化病的局部5-氨基酮戊酸光动力疗法与5%咪喹莫特乳膏的个体内左右比较。
J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1061-5. doi: 10.1111/j.1468-3083.2009.03259.x. Epub 2009 Apr 8.
10
Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis.一项随机、双盲、前瞻性研究,比较外用5-氨基乙酰丙酸甲酯与外用5-氨基乙酰丙酸光动力疗法治疗广泛性头皮光化性角化病的效果。
Br J Dermatol. 2007 Jul;157(1):87-91. doi: 10.1111/j.1365-2133.2007.07946.x. Epub 2007 May 14.

引用本文的文献

1
A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy.一项非随机、开放标签、多中心研究,旨在评估10%氨基乙酰丙酸凝胶联合红光光动力疗法对面部和头皮光化性角化病进行扩大野定向治疗的安全性和耐受性。
J Clin Aesthet Dermatol. 2025 Apr;18(4):44-50.
2
Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care.光化性角化病诊断及治疗反应监测的数字增强方法:个性化皮肤护理的新途径
Cancers (Basel). 2024 Jan 23;16(3):484. doi: 10.3390/cancers16030484.
3
A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions.
光化性角化病现有疗法综述:现状与未来方向。
Am J Clin Dermatol. 2022 May;23(3):339-352. doi: 10.1007/s40257-022-00674-3. Epub 2022 Feb 19.
4
Folic acid conjugated ferritins as photosensitizer carriers for photodynamic therapy.叶酸共轭铁蛋白作为用于光动力疗法的光敏剂载体
Nanoscale. 2015 Jun 21;7(23):10330-3. doi: 10.1039/c5nr01833a.
5
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.咪喹莫特凝胶治疗光化性角化病的成本效用分析:苏格兰视角
Eur J Health Econ. 2016 Apr;17(3):287-304. doi: 10.1007/s10198-015-0679-8. Epub 2015 Mar 21.